Your browser doesn't support javascript.
loading
Impact of Center Volume on Chronic Graft Versus Host Disease in Patients With Allogeneic Stem Cell Transplantation.
Shimomura, Yoshimitsu; Kitamura, Tetsuhisa; Murata, Makoto; Matsuo, Keitaro; Ito, Yuri; Ichinohe, Tatsuo; Hashii, Yoshiko; Goto, Hideki; Kato, Koji; Ishimaru, Fumihiko; Sato, Atsushi; Onizuka, Makoto; Yanagisawa, Atsumi; Ohbiki, Marie; Tabuchi, Ken; Atsuta, Yoshiko; Fukuda, Takahiro; Kanda, Junya; Terakura, Seitaro.
Afiliação
  • Shimomura Y; Department of Hematology, Kobe City Hospital Organization Kobe City Medical Center General Hospital, Chuo-ku, Kobe, Japan; Department of Environmental Medicine and Population Science, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan. Electronic address: shimomura_0119@yahoo.co.jp.
  • Kitamura T; Department of Environmental Medicine and Population Science, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.
  • Murata M; Department of Hematology, Shiga University of Medical Science, Otsu, Shiga, Japan.
  • Matsuo K; Division Cancer Epidemiology and Prevention, Aichi Cancer Center Research Institute, Chikusa-ku, Nagoya Japan.
  • Ito Y; Department of Medical Statistics, Research & Development Center, Osaka Medical and Pharmaceutical University, Takatsuki, Osaka, Japan.
  • Ichinohe T; Department of Hematology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Minami-ku, Hiroshima, Japan.
  • Hashii Y; Department of Pediatrics, Osaka International Cancer Institute, Chuo-ku, Osaka, Japan.
  • Goto H; Division of Laboratory and Transfusion Medicine, Hokkaido University Hospital, Sapporo-shi, Hokkaido, Japan.
  • Kato K; Department of Hematology, Oncology and Cardiovascular Medicine, Kyushu University Hospital, Higashi-ku, Fukuoka, Japan.
  • Ishimaru F; Japanese Red Cross Kanto-Koshinetsu Block Blood Center, Atsugi, Kanagawa, Japan.
  • Sato A; Department of Hematology and Oncology, Miyagi Children's Hospital, Sendai, Miyagi, Japan.
  • Onizuka M; Department of Hematology/Oncology, Tokai University School of Medicine, Isehara, Kanagawa, Japan.
  • Yanagisawa A; Japanese Data Center for Hematopoietic Cell Transplantation, Nagakute, Aichi, Japan.
  • Ohbiki M; Japanese Data Center for Hematopoietic Cell Transplantation, Nagakute, Aichi, Japan; Department of Registry Science for Transplant and Cellular Therapy, Aichi Medical University School of Medicine, Nagakute, Aichi, Japan; Department of Hematology and Oncology, Nagoya University Graduate School of Me
  • Tabuchi K; Japanese Data Center for Hematopoietic Cell Transplantation, Nagakute, Aichi, Japan.
  • Atsuta Y; Japanese Data Center for Hematopoietic Cell Transplantation, Nagakute, Aichi, Japan; Department of Registry Science for Transplant and Cellular Therapy, Aichi Medical University School of Medicine, Nagakute, Aichi, Japan.
  • Fukuda T; Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.
  • Kanda J; Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Sakyo-ku, Kyoto, Japan.
  • Terakura S; Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.
Transplant Cell Ther ; 30(3): 326.e1-326.e14, 2024 Mar.
Article em En | MEDLINE | ID: mdl-38218451
ABSTRACT
Chronic graft-versus-host disease (cGVHD) is a complication of allogeneic hematopoietic stem cell transplantation (HSCT), negatively impacting quality of life (QoL) and increasing the risk of death. Complexity in cGVHD diagnosis and treatment causes significant variations in cGVHD management strategies across medical centers and physicians despite the existence of published guidelines. Thus, we hypothesized that center volume is associated with cGVHD incidence and outcomes after cGVHD develops. This study aimed to evaluate the effect of center volume on the incidence of cGVHD in patients who underwent HSCT and outcomes in patients with cGVHD. Our retrospective study included 28,786 patients who underwent their first HSCT (overall cohort) and 7664 who developed cGVHD (cGVHD cohort). We categorized institutions into quartiles (very low, low, high, and very high) using the number of HSCTs performed during the study period. We assessed cGVHD incidence in overall cohort and overall survival (OS) in cGVHD cohort. The very high-volume group showed significantly higher cGVHD incidence (adjusted hazard ratio [HR], 1.38; 95% confidence interval [CI] 1.30 to 1.46) compared to the very low-volume group. However, the cGVHD incidence was similar among very low-, low- and high-volume groups. Low, high, and very high-volume groups showed significantly higher OS with adjusted HRs of 0.83 (95% CI 0.73 to 0.94), 0.69 (95% CI 0.61 to 0.79), and 0.68 (95% CI 0.60 to 0.76), respectively, compared with the very low-volume group. In conclusion, we revealed a higher incidence of cGVHD in the very high-volume group and a poor survival outcome in the very low-volume group in patients with cGVHD.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Transplante de Células-Tronco Hematopoéticas / Síndrome de Bronquiolite Obliterante / Doença Enxerto-Hospedeiro Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Transplante de Células-Tronco Hematopoéticas / Síndrome de Bronquiolite Obliterante / Doença Enxerto-Hospedeiro Idioma: En Ano de publicação: 2024 Tipo de documento: Article